David is responsible for the development, implementation and execution of central nervous system (CNS) research and development at Spark Therapeutics and supports the clinical development and registration of gene therapies targeting the CNS. Since joining Spark in 2016 as the CNS Preclinical Lead, David has led the preclinical development of Spark’s adeno-associated viral (AAV)-based gene therapy programs in Huntington’s disease and Batten disease, before assuming overall leadership for the CNS group in 2017.
He began his career as a post-doc and became an assistant professor in the Department of Pathology and Cell Biology at Thomas Jefferson University in Philadelphia. During this time, he received funding from the Parkinson’s Disease Foundation to study the role of epigenetic modifications in levodopa-induced dyskinesia and was a collaborator on several grants focusing on the toxicogenetics of heavy metals in the developing CNS and the development of neuroprotective molecules for the treatment of Parkinson’s disease. In 2006, David cofounded Lazarus Therapeutics Inc., to develop both small molecule and biologics for the treatment of neurodegenerative diseases. He has multiple manuscripts published in peer-reviewed journals and numerous abstracts accepted resulting in conference presentations.
David holds a Ph.D. in pathology and cell biology from Thomas Jefferson University.